Prospective study evaluating oncological safety of axillary reverse mapping.
Identifieur interne : 001639 ( PubMed/Corpus ); précédent : 001638; suivant : 001640Prospective study evaluating oncological safety of axillary reverse mapping.
Auteurs : Eduardo Schunemann ; Maíra Teixeira D Ria ; Janiceli Blanca Carlotto Hablich Silvestre ; Plínio Gasperin ; Teresa Cristina Santos Cavalcanti ; Vinicius Milani BudelSource :
- Annals of surgical oncology [ 1534-4681 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Arm (pathology), Arm (surgery), Axilla, Breast Neoplasms (pathology), Breast Neoplasms (surgery), Carcinoma, Ductal, Breast (secondary), Carcinoma, Ductal, Breast (surgery), Carcinoma, Lobular (secondary), Carcinoma, Lobular (surgery), Drainage, Female, Follow-Up Studies, Humans, Lymph Nodes (pathology), Lymph Nodes (surgery), Lymphatic Metastasis, Lymphatic Vessels (pathology), Lymphatic Vessels (surgery), Lymphedema (etiology), Lymphedema (prevention & control), Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Sentinel Lymph Node Biopsy (adverse effects).
- MESH :
- adverse effects : Sentinel Lymph Node Biopsy.
- etiology : Lymphedema.
- pathology : Arm, Breast Neoplasms, Lymph Nodes, Lymphatic Vessels.
- prevention & control : Lymphedema.
- secondary : Carcinoma, Ductal, Breast, Carcinoma, Lobular.
- surgery : Arm, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Lymph Nodes, Lymphatic Vessels.
- Adult, Aged, Aged, 80 and over, Axilla, Drainage, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies.
Abstract
Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymph nodes affects oncological risk. The present study evaluated the presence of metastases in ARM nodes.
DOI: 10.1245/s10434-014-3626-5
PubMed: 24599413
Links to Exploration step
pubmed:24599413Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospective study evaluating oncological safety of axillary reverse mapping.</title><author><name sortKey="Schunemann, Eduardo" sort="Schunemann, Eduardo" uniqKey="Schunemann E" first="Eduardo" last="Schunemann">Eduardo Schunemann</name><affiliation><nlm:affiliation>Department of Gynecology and Obstetrics, Clinical Hospital of Federal University of Paraná, Curitiba, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="D Ria, Maira Teixeira" sort="D Ria, Maira Teixeira" uniqKey="D Ria M" first="Maíra Teixeira" last="D Ria">Maíra Teixeira D Ria</name></author><author><name sortKey="Silvestre, Janiceli Blanca Carlotto Hablich" sort="Silvestre, Janiceli Blanca Carlotto Hablich" uniqKey="Silvestre J" first="Janiceli Blanca Carlotto Hablich" last="Silvestre">Janiceli Blanca Carlotto Hablich Silvestre</name></author><author><name sortKey="Gasperin, Plinio" sort="Gasperin, Plinio" uniqKey="Gasperin P" first="Plínio" last="Gasperin">Plínio Gasperin</name></author><author><name sortKey="Cavalcanti, Teresa Cristina Santos" sort="Cavalcanti, Teresa Cristina Santos" uniqKey="Cavalcanti T" first="Teresa Cristina Santos" last="Cavalcanti">Teresa Cristina Santos Cavalcanti</name></author><author><name sortKey="Budel, Vinicius Milani" sort="Budel, Vinicius Milani" uniqKey="Budel V" first="Vinicius Milani" last="Budel">Vinicius Milani Budel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24599413</idno><idno type="pmid">24599413</idno><idno type="doi">10.1245/s10434-014-3626-5</idno><idno type="wicri:Area/PubMed/Corpus">001639</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001639</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prospective study evaluating oncological safety of axillary reverse mapping.</title><author><name sortKey="Schunemann, Eduardo" sort="Schunemann, Eduardo" uniqKey="Schunemann E" first="Eduardo" last="Schunemann">Eduardo Schunemann</name><affiliation><nlm:affiliation>Department of Gynecology and Obstetrics, Clinical Hospital of Federal University of Paraná, Curitiba, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="D Ria, Maira Teixeira" sort="D Ria, Maira Teixeira" uniqKey="D Ria M" first="Maíra Teixeira" last="D Ria">Maíra Teixeira D Ria</name></author><author><name sortKey="Silvestre, Janiceli Blanca Carlotto Hablich" sort="Silvestre, Janiceli Blanca Carlotto Hablich" uniqKey="Silvestre J" first="Janiceli Blanca Carlotto Hablich" last="Silvestre">Janiceli Blanca Carlotto Hablich Silvestre</name></author><author><name sortKey="Gasperin, Plinio" sort="Gasperin, Plinio" uniqKey="Gasperin P" first="Plínio" last="Gasperin">Plínio Gasperin</name></author><author><name sortKey="Cavalcanti, Teresa Cristina Santos" sort="Cavalcanti, Teresa Cristina Santos" uniqKey="Cavalcanti T" first="Teresa Cristina Santos" last="Cavalcanti">Teresa Cristina Santos Cavalcanti</name></author><author><name sortKey="Budel, Vinicius Milani" sort="Budel, Vinicius Milani" uniqKey="Budel V" first="Vinicius Milani" last="Budel">Vinicius Milani Budel</name></author></analytic><series><title level="j">Annals of surgical oncology</title><idno type="eISSN">1534-4681</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Arm (pathology)</term><term>Arm (surgery)</term><term>Axilla</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (surgery)</term><term>Carcinoma, Ductal, Breast (secondary)</term><term>Carcinoma, Ductal, Breast (surgery)</term><term>Carcinoma, Lobular (secondary)</term><term>Carcinoma, Lobular (surgery)</term><term>Drainage</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymph Nodes (pathology)</term><term>Lymph Nodes (surgery)</term><term>Lymphatic Metastasis</term><term>Lymphatic Vessels (pathology)</term><term>Lymphatic Vessels (surgery)</term><term>Lymphedema (etiology)</term><term>Lymphedema (prevention & control)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Prospective Studies</term><term>Sentinel Lymph Node Biopsy (adverse effects)</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Sentinel Lymph Node Biopsy</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Arm</term><term>Breast Neoplasms</term><term>Lymph Nodes</term><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Ductal, Breast</term><term>Carcinoma, Lobular</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Arm</term><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Carcinoma, Lobular</term><term>Lymph Nodes</term><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Axilla</term><term>Drainage</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymph nodes affects oncological risk. The present study evaluated the presence of metastases in ARM nodes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24599413</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>06</Day></DateCreated><DateCompleted><Year>2015</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-4681</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of surgical oncology</Title><ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Prospective study evaluating oncological safety of axillary reverse mapping.</ArticleTitle><Pagination><MedlinePgn>2197-202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-014-3626-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Axillary reverse mapping (ARM) is a new technique developed with the aim of reducing lymphedema rates by preserving lymphatic drainage of the upper limbs during sentinel lymph node biopsy and axillary lymph node dissection (ALND). However, it is unclear whether preservation of these lymph nodes affects oncological risk. The present study evaluated the presence of metastases in ARM nodes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 45 patients underwent ARM during ALND. Blue dye was used for ARM nodes localization. All axillary lymph nodes, including ARM nodes, were removed and sent separately for pathological evaluation of metastases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ARM identification was achieved in 40/45 patients (88.9 %). The average number of removed ARM nodes was 1.9. ARM nodes metastasis occurred in 10 of 40 patients (25 %). Patients with an axilla extensively affected by cancer had an elevated risk of metastasis to the arm's lymph nodes (p < 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The rate of arm lymph nodes compromised by metastases calls into question the viability of the ARM technique. Larger studies may point to particular patient profiles for which ARM can be safely use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schunemann</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Clinical Hospital of Federal University of Paraná, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dória</LastName><ForeName>Maíra Teixeira</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Silvestre</LastName><ForeName>Janiceli Blanca Carlotto Hablich</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Gasperin</LastName><ForeName>Plínio</ForeName><Initials>P</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Cavalcanti</LastName><ForeName>Teresa Cristina Santos</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Budel</LastName><ForeName>Vinicius Milani</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg Oncol</MedlineTA><NlmUniqueID>9420840</NlmUniqueID><ISSNLinking>1068-9265</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2013 Oct 9;310(14):1455-61</RefSource><PMID Version="1">24101169</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Nov 10;26(32):5213-9</RefSource><PMID Version="1">18838709</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2012 Aug;38(8):657-61</RefSource><PMID Version="1">22607749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2007 Sep;14(9):2490-6</RefSource><PMID Version="1">17549570</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Nov 20;27(33):5547-51</RefSource><PMID Version="1">19826123</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Aug 20;25(24):3657-63</RefSource><PMID Version="1">17485711</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2009 Oct;198(4):482-7</RefSource><PMID Version="1">19800452</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2007 Jun;14(6):1890-5</RefSource><PMID Version="1">17479341</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Breast Cancer. 2012 Mar;15(1):91-7</RefSource><PMID Version="1">22493634</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Control. 2012 Oct;19(4):267-76</RefSource><PMID Version="1">23037494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2007 Mar;245(3):452-61</RefSource><PMID Version="1">17435553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2012 Mar;105(3):229-34</RefSource><PMID Version="1">21913193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer. 2011 Jul;18(3):174-80</RefSource><PMID Version="1">21331463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2009 Sep;16(9):2459-63</RefSource><PMID Version="1">19506954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Surg. 2008 May;206(5):1038-42; discussion 1042-4</RefSource><PMID Version="1">18471751</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2011 Dec;137(12):1869-74</RefSource><PMID Version="1">21935615</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2011 Feb 9;305(6):569-75</RefSource><PMID Version="1">21304082</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Sep;15(9):2550-5</RefSource><PMID Version="1">18618185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer. 2010 Jul;17(3):155-7</RefSource><PMID Version="1">19789947</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2013 Dec;39(12):1341-5</RefSource><PMID Version="1">24113621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2013 Aug;39(8):880-6</RefSource><PMID Version="1">23735162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2012 Jul 1;106(1):89-93</RefSource><PMID Version="1">22258666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Educ Couns. 2007 Jun;66(3):311-8</RefSource><PMID Version="1">17331692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2013 Oct;20(10):3303-7</RefSource><PMID Version="1">23975287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trials. 2013;14:111</RefSource><PMID Version="1">23782712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Apr 20;23(12):2694-702</RefSource><PMID Version="1">15837984</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Jan;15(1):390-1; author reply 392-3</RefSource><PMID Version="1">17990039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Jun 1;116(11):2543-8</RefSource><PMID Version="1">20336790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jun;14(7):609-18</RefSource><PMID Version="1">23683750</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2010 Feb;119(3):529-35</RefSource><PMID Version="1">19842033</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4047480</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24599413</ArticleId><ArticleId IdType="doi">10.1245/s10434-014-3626-5</ArticleId><ArticleId IdType="pmc">PMC4047480</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001639 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001639 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24599413
|texte= Prospective study evaluating oncological safety of axillary reverse mapping.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24599413" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |